Research on heart attacks and their treatment. Covers care for older patients, cardiac rehabilitation, rapid testing, and updated diagnostic definitions.
Researchers developed tiny polymer beads that release anti-inflammatory drugs, breaking down into non-toxic components. The particles reduce inflammation and scarring, cutting the area of scar tissue in half and boosting heart function by 10 percent weeks later.
Men who never smoke live longer and have better quality of life than heavy smokers, with an average of 10 years longer lifespan. Physical health deteriorates as the number of cigarettes smoked per day increases.
Long-term follow-up data from the APPROVe trial confirm that rofecoxib substantially increases the risk of stroke, heart attack, and death compared to placebo. The relative risk of reaching cardiovascular events was increased by 79% in the rofecoxib group.
A hospital-based smoking cessation program, along with cardiac rehabilitation referrals, increases quitting rates following a heart attack. Approximately 47% of patients who received these services quit smoking six months later.
A hospital-based case-control study found that pneumococcal vaccination was associated with a 50% lower risk of heart attacks two years after vaccination. The study suggested that the pneumonia vaccine may protect against heart attacks by preventing pneumonia, which has been linked to triggering heart attacks.
A large Danish observational study found that women taking hormone replacement therapy (HRT) who used it on a cyclical basis, through skin or vaginal application, had a reduced risk of heart attacks. This contradicts previous research and suggests that certain HRT regimens may be safer than others.
A meta-analysis of randomized trials found that inhaled anticholinergic agents significantly increase the risk of heart attack, stroke, and cardiovascular death by 58% and 80% respectively. The study suggests clinicians closely monitor patients with COPD taking these medications for potential long-term cardiovascular risks.
Researchers found that long-term use of inhaled anticholinergics for COPD increases the risk of cardiovascular death, heart attacks, or strokes by 58%. Patients with COPD who use these inhalers are at high risk of excess serious cardiovascular events.
Researchers have developed a new class of heart disease medication that reduces the development of high-risk blockages in arteries. The study found that darapladib, which specifically inhibits lipoprotein-associated phospholipase A2, decreased the size and number of advanced plaques that cause heart attacks and strokes.
A study in mice found that socially isolated heart attack victims showed five to eight times more damage to neurons in one part of the brain than those that lived with others. Inflammation and increased stress hormone levels were also observed in isolated mice, contributing to the increased neuronal damage.
A study published in Journal of Empirical Legal Studies found that Lipitor's advertising omits crucial information relevant to women, raising concerns about its safety. The study questions Pfizer's claims of clinical proof for Lipitor's effectiveness in preventing heart attacks in women with multiple risk factors.
Researchers identify aldehyde dehydrogenase 2 (ALDH2) as a crucial enzyme in reducing cellular damage from free radicals. Activation of ALDH2 increases its activity during heart attacks, leading to a significant drop in associated damage and potential applications for treating various diseases.
Researchers at Indiana University have discovered a molecule that could lead to new treatments for heart attacks and protect hearts during open heart surgery. The compound, Alda-1, was found to activate an enzyme that reduces cell death caused by lack of blood flow to the heart.
A new blood analysis technique identified markers that could improve treatment and save lives for patients having a heart attack. By analyzing hundreds of molecular markers, doctors can confirm the presence of a heart attack within minutes, allowing for rapid treatment.
Researchers developed a novel method using human embryonic stem cell secretions to reduce tissue injury after a heart attack. The approach significantly improved heart function and reduced tissue death by 60%, offering a promising therapeutic option for heart attack patients.
A recent study found that exposure to fine particles and black carbon from traffic sources was associated with ST-segment depression in patients with coronary artery disease. The study suggests that air pollution can affect heart health through inflammation of the heart muscle or reduced blood flow, highlighting the need for vigilance ...
Researchers have found that farnesylated progerin, not just its non-farnesylated form, can cause symptoms of disease in individuals with Hutchinson-Gilford progeria syndrome (HGPS). Meanwhile, a new study suggests that neural stem cell transplantation may offer hope for treating spinal muscular atrophy (SMA) by improving the survival a...
The APPRAISE-I trial found a non-statistically significant trend that patients taking apixaban with aspirin or clopidogrel had lower incidence of heart attack, stroke, and cardiovascular death, compared to those taking a placebo. However, bleeding complications were a concern, especially at higher doses.
A Phase II study found trends suggesting apixaban reduces heart attack, stroke risk but increases bleeding among higher doses, warranting further study.
Researchers developed a new method for early detection of heart attacks using metabolite profiling, detecting changes in blood samples 10 minutes after the event. The approach has potential to improve early treatment and survival rates.
Researchers are exploring new biomarkers to detect myocardial infarction, which could lead to faster diagnosis and improved treatment outcomes. Currently, cardiac troponin is the gold standard for diagnosing myocardial necrosis, but its limitations include delayed detection and low sensitivity to ischemia.
The TRANSCEND study enrolled nearly 6,000 people worldwide who are intolerant to ACE inhibitors and found that telmisartan reduced the outcome of cardiovascular death, heart attack, or stroke by a significant 13% compared to placebo. Fewer patients receiving telmisartan were hospitalized for any cardiovascular reason.
The BEAUTIFUL study shows ivabradine significantly reduces hospitalization for fatal and non-fatal myocardial infarction by 36% and coronary revascularisation by 30% in high-heart-rate patients. Ivabradine is safe and well-tolerated, even when used with other cardiovascular drugs.
The TRANSCEND study found that telmisartan modestly reduced the outcome of cardiovascular death, heart attack, stroke, and hospitalization for heart failure. Additionally, fewer patients receiving telmisartan were hospitalized for any cardiovascular reason compared to placebo.
The study found that ivabradine reduced coronary secondary outcomes, including fatal and non-fatal heart attacks by 36% and coronary revascularisation by 30%, in patients with a heart rate of above 70 bpm. Elevated heart rate was also identified as a strong independent risk factor for cardiovascular death and disease.
Diabetic patients face accelerated atherosclerosis, increased risk of restenosis and late mortality when undergoing PCI. DES has been associated with mortality benefit in patients with multivessel disease, but results are mixed for diabetic patients.
Researchers found that patients with incomplete heart attacks are at a higher risk of having another heart attack after discharge. The study suggests that some patients may not receive optimal treatment due to incorrect risk assessment.
A randomized controlled trial found that high-dose tirofiban improved ST-segment resolution and clinical outcomes for STEMI patients undergoing primary coronary angioplasty. The study showed lower overall mortality and less urgent repeat PCI in the tirofiban group.
A new study found that a protein produced by fat cells may increase the risk of heart attack in older adults. Adiponectin levels were associated with a higher risk of heart disease events, particularly among those with high levels.
A recent study published in Obesity found that having excess fat around the heart may increase the risk of heart attacks. Researchers discovered that the volume of pericardial fat was related to the development of calcified coronary plaque, a marker for increased cardiovascular risk.
A new study published in the Emergency Medicine Journal found that emergency room doctors correctly identify patients with heart attack symptoms even when laboratory tests have not yet confirmed it. The study analyzed data from over 4,000 patients and showed that physicians are relying on their clinical impression to diagnose heart att...
Researchers found that the apolipoprotein B100 (ApoB)/apolipoprotein A1 (Apo A1) ratio was almost twice as powerful a predictor of heart attack risk as traditional cholesterol ratios. This discovery could lead to improved cardiovascular disease prevention and treatment strategies.
A new study published in Annals of Family Medicine found that optimistic perceptions of cardiovascular risk are associated with a three times lower incidence of death from heart attacks and strokes among men. However, the study did not find a similar association among women.
A study found that patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD) were less likely to use recommended medications after a heart attack, but 1-year adherence rates were similar for both groups. Rates of medication use varied significantly among different types of drugs.
A meta-analysis of randomized trials suggests that an invasive treatment strategy is associated with reduced risk of rehospitalization, heart attack, or death in men and high-risk women with certain coronary syndromes. However, low-risk women may have an increased risk of heart attack or death with this treatment.
A study found that drug-releasing stents decreased the need for repeat revascularization procedures by approximately 18% compared to bare-metal stents. The risk of death or heart attack also showed a small decrease, but no significant difference in overall mortality rates.
Two studies in the FASEB Journal describe key findings on atherosclerosis, including the role of ROCK1 protein in reducing inflammation. Targeting lipid mediators and mechanisms used to make them could lead to new anti-atherosclerosis therapies.
Research by Mayo Clinic found that people with lower incomes and education levels are more likely to die after a heart attack. The study analyzed data from 705 patients treated for heart attack between 2002 and 2006, showing survival rates were lowest for those with the lowest income and education.
A multicenter, randomized, double-blind study found that Chinese red yeast rice reduced the risk of repeat heart attacks and cardiovascular mortality by one-third. The study showed a significant reduction in cancer mortality as well.
Research suggests that low levels of vitamin D are associated with a higher risk of heart attack in men. A study of 454 men found that those with vitamin D deficiency had an increased risk compared to those with sufficient levels.
Researchers at Mayo Clinic found that heart patients who met regularly with cardiac 'disease managers' for three years had better control of risk factors and lower death rates. The approach demonstrated clear clinical benefits, including improved cholesterol levels, blood pressure, and medication compliance.
A study by UT Southwestern Medical Center has linked amphetamine abuse to a higher risk of heart attacks in young adults. Researchers analyzed data from over 3 million people and found a significant correlation between amphetamine abuse and heart attack diagnoses.
Computed tomography angiography (CTA) is a quicker and cheaper way to screen patients with chest pain for low-risk cardiac problems. Studies show CTA can accurately identify safe patients for discharge, reducing hospital admissions and testing costs.
A new calcium scoring method takes into account plaque distribution to predict heart attack risk, showing a significant association between diabetes and increased coronary artery calcification. The study found that the location of calcium in arteries is crucial in estimating patient risk.
The HORIZONS-AMI trial shows that bivalirudin reduces adverse clinical events by 24%, mortality by 33%, and cardiac mortality by 38% compared to heparin and GPI in heart attack patients. This is the largest study ever to focus on anticoagulant medications in STEMI patients undergoing primary PCI.
The HORIZONS AMI trial found bivalirudin significantly reduces major bleeding and cardiovascular events in STEMI patients undergoing angioplasty. The study showed a 24% reduction in net adverse clinical events and a 33% decrease in overall mortality at 30 days.
A study published in Archives of Internal Medicine found that heart attack patients with acute kidney injury have a persistent risk of death after hospital discharge, with no significant decrease over time.
A randomized trial found patients given beta-blockers after non-cardiac surgery had a higher risk of death or stroke compared to those given placebo, while having a lower risk of non-fatal heart attacks. However, these medications may not outweigh the increased risk of cardiovascular complications.
A major study found that beta-blockers like metoprolol may increase the risk of death and major stroke in patients undergoing non-cardiac surgery. The POISE trial showed that while metoprolol reduces heart attack risk, it increases stroke and death risk, highlighting the need for caution in its use around surgery time.
Researchers found that darapladib safely and effectively lowers Lp-PLA2 activity, an enzyme associated with inflammation and increased risk for heart attack and stroke. The drug may reduce plaque inflammation and lower rates of clot formation among patients with coronary heart disease.
A carotid bruit, a 'sound' over the carotid artery indicating blockage, substantially increases the risk of cardiovascular death and heart attack. The meta-analysis of 22 studies found patients with carotid bruits were around twice as likely to suffer a heart attack.
Researchers have discovered that TPO, a naturally occurring protein, can protect the heart against damage during a heart attack. The study found that administering a single dose of TPO to rats decreased permanent muscle damage and increased heart function after a heart attack.
A new study reveals that women are more likely to experience atypical symptoms such as nausea and jaw pain during a heart attack, leading to delayed treatment. Women were also less likely to receive life-saving treatments like beta blockers, statins, and angioplasty compared to men.
Researchers found that young women with heart attacks often misattributed their symptoms to fatigue or other conditions, failing to connect them with a heart condition. The study suggests that there are large gaps in understanding the symptoms and reasons for delaying prompt care among this age group.
A JAMA study found that hemoglobin-based blood substitutes are associated with a 30% increased risk of death and a 2.7 times increased risk of heart attack in patients. The researchers argue for stricter regulations on the development of these products to prevent future safety concerns.
A study found that India will account for 60% of the world's heart disease burden by 2010, with a higher rate of severe cases among younger patients. The country also has a lower age at diagnosis compared to developed countries.
The study found that angiographic in-segment late loss was significantly less in the everolimus-releasing stent group compared to the paclitaxel group. The use of everolimus stents resulted in a significant reduction in composite major adverse cardiac events at 9 months and 1 year.
A recent study published in Circulation: Journal of the American Heart Association found that patients admitted with heart attacks during off-hours receive slower and less comprehensive care. Despite this, there is no significant difference in in-hospital death rates between those arriving during regular hours and off-hours.
Researchers developed a nano-bio-chip device that analyzes saliva to detect proteins associated with heart attack, offering a non-invasive and rapid diagnostic tool. The test can identify current heart attacks and predict future risk, potentially saving lives and preventing damage from cardiac disease.
Scientists at the University of North Carolina at Chapel Hill found that not all heart cells respond equally to the same cue before differentiating. This discovery may lead to advances in understanding and treating congenital heart disease and heart attacks by identifying multiple types of heart cell progenitors.